Added value of CA19-9 response to recist staging in predicting resectability of locally advanced pancreatic cancer following induction chemotherapy

Added value of CA19-9 response to recist staging in predicting resectability of locally advanced pancreatic cancer following induction chemotherapy

Introduction: Determining the resectability of locally advanced pancreatic cancer (LAPC) is difficult as computed tomography RECIST-assessment often underestimates the impact of induction chemotherapy. Method: Post-hoc analysis within a prospective mono-centre study in consecutive patients with LAPC...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Pancreatology : official journal of the International Association of Pancreatology (IAP) ... [et al.] 2017-09, Vol.17 (4), p.S45-S45
Hauptverfasser: van Veldhuisen, Eran, Vogel, Jantien A., Busch, Olivier R.C., van Laarhoven, Hanneke W.M., van Lienden, Krijn P., Wilmink, Johanna W., Marsman, Hendrik A., Besselink, Marc G.
Format: Artikel
Sprache:eng
Schlagworte:
Chemotherapy
Pancreatic cancer
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Introduction: Determining the resectability of locally advanced pancreatic cancer (LAPC) is difficult as computed tomography RECIST-assessment often underestimates the impact of induction chemotherapy. Method: Post-hoc analysis within a prospective mono-centre study in consecutive patients with LAPC (according to the DPCG criteria; >90 arterial or >270 venous involvement) who underwent 3 months of induction chemotherapy.
ISSN:1424-3903
1424-3911
DOI:10.1016/j.pan.2017.07.148